Alexion Continues to Diversify its Portfolio with Achillion Acquisition
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 10 (Table of Contents)
Published: 23 Oct-2019
DOI: 10.3833/pdr.v2019.i10.2464 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to build out its pipeline beyond Soliris® (eculizumab), Alexion Pharmaceuticals has agreed to acquire Achillion Pharmaceuticals for US$930 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS